Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Raw Materials: 2010-2020

Historic Raw Materials for UNITED THERAPEUTICS (UTHR) over the last 9 years, with Mar 2020 value amounting to $20.1 million.

  • UNITED THERAPEUTICS's Raw Materials fell 9.87% to $20.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $20.1 million, marking a year-over-year decrease of 9.87%. This contributed to the annual value of $21.1 million for FY2019, which is 13.17% down from last year.
  • According to the latest figures from Q1 2020, UNITED THERAPEUTICS's Raw Materials is $20.1 million, which was down 4.74% from $21.1 million recorded in Q4 2019.
  • UNITED THERAPEUTICS's 5-year Raw Materials high stood at $29.1 million for Q2 2017, and its period low was $19.3 million during Q3 2019.
  • For the 3-year period, UNITED THERAPEUTICS's Raw Materials averaged around $22.9 million, with its median value being $22.3 million (2019).
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Raw Materials grew by 17.34% in 2017, and later fell by 25.77% in 2019.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Raw Materials stood at $25.4 million in 2016, then increased by 9.84% to $27.9 million in 2017, then decreased by 12.90% to $24.3 million in 2018, then dropped by 13.17% to $21.1 million in 2019, then fell by 9.87% to $20.1 million in 2020.
  • Its Raw Materials stands at $20.1 million for Q1 2020, versus $21.1 million for Q4 2019 and $19.3 million for Q3 2019.